目的 神经内分泌肿瘤是威胁患者生命的神经系统疾病。神经内分泌肿瘤患者免疫力下降是造成肿瘤恶化的原因之 一。神经内分泌肿瘤与免疫分子MAVS的关系尚需研究。方法 以我院肿瘤科收治的468名神经内分泌肿瘤患者为研究 对象（包括神经内分泌肿瘤患者207例和重症神经内分泌肿瘤患者161例），同时以207例健康志愿者作为对照。使 用western blot检测治疗前后神经内分泌肿瘤患者和健康志愿者血细胞中MAVS的水平。分析MAVS的水平与神经内 分泌肿瘤之间的相关性。结果 神经内分泌肿瘤患者血细胞中MAVS的蛋白水平显著高于健康志愿者血细胞中MAVS的 蛋白水平（P＜0.05）。治疗后神经内分泌肿瘤患者血细胞中MAVS的蛋白表达水平下降。重度神经内分泌肿瘤患者 血细胞中MAVS的蛋白水平显著高于一般神经内分泌肿瘤患者血细胞中MAVS的蛋白水平（P＜0.05）。神经内分泌肿 瘤患者血细胞中MAVS的蛋白水平与神经内分泌肿瘤的恶化程度具有正相关性。结论 神经内分泌肿瘤患者血细胞中 MAVS可能是神经内分泌肿瘤患者的特异生物标志物。MAVS水平与神经内分泌肿瘤的恶化程度具有密切正相关性。

Objective Neuroendocrine tumor is a nervous system disease that threatens the life of patients. The decline of immunity in patients with neuroendocrine tumors is one of the causes of the deterioration of the tumor. The relationship between neuroendocrine tumor and immune molecule MAVS remains to be studied. Methods 468 patients with neuroendocrine tumors were admitted to hospital as the research object (including 161 cases of neuroendocrine tumors and 207 patients with severe neuroendocrine cancer patients), and 207 healthy volunteers were considered as control. Protein levels of MAVS in blood cells of neuroendocrine cancer patients and healthy volunteers were measured by western blot assay before and after treatment. The correlation between the levels of MAVS and the neuroendocrine tumor was analyzed. Results The protein levels of MAVS in the blood cells of neuroendocrine cancer patients were significantly higher than that in the healthy volunteers (P<0.05). The expression of MAVS in the blood cells of neuroendocrine cancer patients was decreased after treatment. Protein levels of MAVS in the blood cells of severe neuroendocrine cancer patients were significantly higher than that of patients with general neuroendocrine tumor (P<0.05). The MAVS in the blood cells is positively correlated with the degree of deterioration of neuroendocrine tumors. Conclusion The MAVS in the blood cells could be a specific biomarker for neuroendocrine tumor diagnosis. The levels of MAVS were positively correlated with the degree of deterioration of neuroendocrine tumors.